Enzyme studies in tardive dyskinesia. I. One-year biochemical follow-up.
Over a 1-year period we followed 12 female in-patients with and 13 without persistent tardive dyskinesia. Clinical signs of tardive dyskinesia as well as plasma dopamine-beta-hydroxylase and platelet monoamine oxidase activities remained stable over time in spite of medication changes. Tardive dyskinesia was associated with higher plasma dopamine-beta-hydroxylase and lower monoamine oxidase activities, both initially and at follow-up. In two patients, an apparent elevation in dopamine-beta-hydroxylase activity preceded the onset of clinical dyskinesia, suggesting that elevated plasma dopamine-beta-hydroxylase activity might be a potential risk marker for the development of tardive dyskinesia.
D000368:Aged; D001792:Blood Platelets / Q000201:enzymology; D004299:Dopamine beta-Hydroxylase / Q000097:blood; D004409:Dyskinesia, Drug-Induced / Q000201:enzymology*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008875:Middle Aged; D008995:Monoamine Oxidase / Q000097:blood
D004299:Dopamine beta-Hydroxylase; D008995:Monoamine Oxidase